medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2016-17-38-41medsovet-1579Research ArticleНЕВРОЛОГИЯNEUROLOGYТерапия постинсультных когнитивных нарушенийTherapy of poststroke cognitive impairmentЕмелинА. Ю.EmelinA. Yu.

д.м.н.

The S.M. Kirov Military Medical Academy, St. Petersburg 

Военно-медицинская академия им. С.М. Кирова, Санкт-ПетербургRussian Federation2016301220160173841Copyright © Емелин А.Ю., 20162016Емелин А.Ю.Emelin A.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1579

В статье рассмотрены основные вопросы этиологии и патогенеза постинсультных сосудистых когнитивных нарушений. Представлены исторические этапы формирования концепции постинсультной деменции. Обсуждены подходы к профилактике и терапевтической коррекции постинсультных когнитивных нарушений. Рассмотрены возможности нейротрофической терапии на примере цитиколина. 

The main issues of poststroke cognitive impairment’s etiology and pathogenesis are considered in this article. Historical stages of the poststroke dementia definition are presented. Approaches to prevention and therapeutic correction of poststroke cognitive impairment are discussed. Opportunities of neurotrophic therapy by the example of citicoline are considered. 

когнитивные нарушенияпостинсультные когнитивные нарушениясосудистые когнитивные нарушениядеменцияпостинсультная деменцияпрофилактикалечениецитиколинcognitive impairmentpoststroke cognitive impairmentvascular cognitive impairmentdementiapoststroke dementiapreventiontreatmentciticolineReferencesFerri C et al. Global prevalence of dementia: a Delphi consensus study. Lancet, 2005, 366(9503): 2112-2117.Ferri C et al. Global prevalence of dementia: a Delphi consensus study. Lancet, 2005, 366(9503): 2112-2117.Iemolo F et al. Pathophysiology of vascular dementia. Immun Ageing, 2009, 6: 13.Iemolo F et al. Pathophysiology of vascular dementia. Immun Ageing, 2009, 6: 13.Емелин А.Ю. Когнитивные нарушения при цереброваскулярной болезни. Неврология. Нейропсихиатрия. Психосоматика, 2014, 4: 11-18.Емелин А.Ю. Когнитивные нарушения при цереброваскулярной болезни. Неврология. Нейропсихиатрия. Психосоматика, 2014, 4: 11-18.Jellinger K. Morphologic diagnosis of «vascular dementia» – a critical update. J. Neurol. Sci., 2008, 270(1–2): 1-12.Jellinger K. Morphologic diagnosis of «vascular dementia» – a critical update. J. Neurol. Sci., 2008, 270(1–2): 1-12.Tomlinson B, Blessed G, Roth M. Observations on the brains of demented old people. J. Neurol. Sci., 1970, 11(3): 205-242.Tomlinson B, Blessed G, Roth M. Observations on the brains of demented old people. J. Neurol. Sci., 1970, 11(3): 205-242.Hachinski V, Lassen N, Marshall J. Multi-infarct dementia. A case of mental deterioration in the elderly. Lancet, 1974, 2(7874): 207-210.Hachinski V, Lassen N, Marshall J. Multi-infarct dementia. A case of mental deterioration in the elderly. Lancet, 1974, 2(7874): 207-210.Tatemichi T et al. Cognitive impairment after stroke: frequency, patterns, and relationship to functional abilities. J. neurol. neurosurg. psychiatry, 1994, 57(2): 202-207.Tatemichi T et al. Cognitive impairment after stroke: frequency, patterns, and relationship to functional abilities. J. neurol. neurosurg. psychiatry, 1994, 57(2): 202-207.Gorelick P et al. Risk factors for dementia associated with multiple cerebral infarcts: a case– control analysis in predominantly African– American hospital–based patients. Arch. Neurol., 1993, 50(7): 714-720.Gorelick P et al. Risk factors for dementia associated with multiple cerebral infarcts: a case– control analysis in predominantly African– American hospital–based patients. Arch. Neurol., 1993, 50(7): 714-720.Ivan C et al. Dementia after stroke. The Framing ham Study. Stroke, 2004, 35(6): 1264-1268.Ivan C et al. Dementia after stroke. The Framing ham Study. Stroke, 2004, 35(6): 1264-1268.Censori B et al. Dementia after first stroke. Stroke, 1996, 27(7): 1205-1210.Censori B et al. Dementia after first stroke. Stroke, 1996, 27(7): 1205-1210.Pohjasvaara T et al. Dementia three months after stroke: baseline frequency and effect of different definitions of dementia in the Helsinki Stroke Aging Memory Study (SAM) cohort. Stroke, 1997, 28(4): 785-792.Pohjasvaara T et al. Dementia three months after stroke: baseline frequency and effect of different definitions of dementia in the Helsinki Stroke Aging Memory Study (SAM) cohort. Stroke, 1997, 28(4): 785-792.Leys D et al. Poststroke dementia. Neurology, 2005, 4(Is.11): 752-759.Leys D et al. Poststroke dementia. Neurology, 2005, 4(Is.11): 752-759.Breteler M еt al. Cardiovascular disease and distribution of cognitive function in elderly people: the Rotterdam Study. BMJ, 1994, 308(6944): 1604-1608.Breteler M еt al. Cardiovascular disease and distribution of cognitive function in elderly people: the Rotterdam Study. BMJ, 1994, 308(6944): 1604-1608.Altieri M et al. Delayed poststroke dementia A 4-year follow-up study. Neurology, 2004, 62: 2193-2197.Altieri M et al. Delayed poststroke dementia A 4-year follow-up study. Neurology, 2004, 62: 2193-2197.Емелин А.Ю. и др. Постинсультные расстройства когнитивных функций (клинико-нейровизуализационное исследование). Неврология. Нейропсихиатрия. Психосоматика, Специ- альный выпуск: Инсульт, 2013, 2: 9-15.Емелин А.Ю. и др. Постинсультные расстройства когнитивных функций (клинико-нейровизуализационное исследование). Неврология. Нейропсихиатрия. Психосоматика, Специ- альный выпуск: Инсульт, 2013, 2: 9-15.Hénon H et al. Poststroke dementia. Incidence and relationship to prestroke cognitive decline / H. Hénon. Neurology, 2001, 57(7): 1216-1222.Hénon H et al. Poststroke dementia. Incidence and relationship to prestroke cognitive decline / H. Hénon. Neurology, 2001, 57(7): 1216-1222.Abbott R et al. Walking and dementia in physically capable elderly men. JAMA, 2004, 292(12): 1447-1453.Abbott R et al. Walking and dementia in physically capable elderly men. JAMA, 2004, 292(12): 1447-1453.Chan A et al. Efficacy of a vitamin/nutriceutical formulation for early-stage Alzheimer’s disease: a 1-year, open-label pilot study with an 16-month caregiver extension. Am. J. Alzheimers Dis. Other Demen.,– 2008, 23(6): 571-85.Chan A et al. Efficacy of a vitamin/nutriceutical formulation for early-stage Alzheimer’s disease: a 1-year, open-label pilot study with an 16-month caregiver extension. Am. J. Alzheimers Dis. Other Demen.,– 2008, 23(6): 571-85.Scrameas N et al. Mediterranean diet and risk for Alzheimer`s disease. Ann. Neurol., 2006, 59(6): 877-879.Scrameas N et al. Mediterranean diet and risk for Alzheimer`s disease. Ann. Neurol., 2006, 59(6): 877-879.Forette F et al. Prevention of dementia in randomised double–blind placebo–controlled Systolic Hypertension in Europe (Syst–Eur) trial. Lancet, 1998, 352: 1347-1351.Forette F et al. Prevention of dementia in randomised double–blind placebo–controlled Systolic Hypertension in Europe (Syst–Eur) trial. Lancet, 1998, 352: 1347-1351.Tzourio C et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch. Intern. Med., 2003, 163(9): 1069-1075.Tzourio C et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch. Intern. Med., 2003, 163(9): 1069-1075.Erkinjuntti T et al. Emerging Therapies for Vascular Dementia and Vascular Cognitive Impairment. Stroke, 2004, 35: 1010.Erkinjuntti T et al. Emerging Therapies for Vascular Dementia and Vascular Cognitive Impairment. Stroke, 2004, 35: 1010.Mellon L et al.Cognitive impairment six months after ischaemic stroke: a profile from the ASPIRE-S study. BMC Neurol., 2015, 15(1): 288.Mellon L et al.Cognitive impairment six months after ischaemic stroke: a profile from the ASPIRE-S study. BMC Neurol., 2015, 15(1): 288.Winblad B et al. Therapeutic use of nicergoline. Clin Drug Investig, 2008, 28(9): 533-52.Winblad B et al. Therapeutic use of nicergoline. Clin Drug Investig, 2008, 28(9): 533-52.Pantoni, L. Treatment of vascular dementia: evidence from trials with non-cholinergic drugs. J Neurol Sci., 2004, 226(1–2): 67-70.Pantoni, L. Treatment of vascular dementia: evidence from trials with non-cholinergic drugs. J Neurol Sci., 2004, 226(1–2): 67-70.Le Bars P et al. A placebo–controlled, double– blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA, 1997, 278: 1327-1332.Le Bars P et al. A placebo–controlled, double– blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA, 1997, 278: 1327-1332.Wilkinson D et al. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology, 2003, 61(4): 479-86.Wilkinson D et al. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology, 2003, 61(4): 479-86.Craig D, Birks J. Galantamine for vascular cognitive impairment. Cochrane Database Syst Rev, 2006, 25(1): CD004746.Craig D, Birks J. Galantamine for vascular cognitive impairment. Cochrane Database Syst Rev, 2006, 25(1): CD004746.Ballard C et al. Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Curr. Med. Res Opin., 2008, 9: 2561-74.Ballard C et al. Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Curr. Med. Res Opin., 2008, 9: 2561-74.Orgogozo J-M et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia. A randomized, placebo-controlled trial (MMM 300). Stroke, 2002, 33: 1834-1839.Orgogozo J-M et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia. A randomized, placebo-controlled trial (MMM 300). Stroke, 2002, 33: 1834-1839.Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev, 2005, 18(2): CD000269.Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev, 2005, 18(2): CD000269.Grieb P. Neuroprotective Properties of Citicoline: Facts, Doubts and Unresolved Issues. CNS Drugs, 2014, 28(3): 185-193.Grieb P. Neuroprotective Properties of Citicoline: Facts, Doubts and Unresolved Issues. CNS Drugs, 2014, 28(3): 185-193.Secades J, Lorenzo J. Citicoline: pharmacological and clinical review, 2006 update. Methods Find. Exp. Clin. Pharmacol., 2006, 28(Suppl. B): 1-56.Secades J, Lorenzo J. Citicoline: pharmacological and clinical review, 2006 update. Methods Find. Exp. Clin. Pharmacol., 2006, 28(Suppl. B): 1-56.Conant R, Schauss AG. Therapeutic Applications of Citicoline for Stroke and Cognitive Dysfunction in the Elderly: A Review of the Literature. Alternative Medicine Review, 2004, 9(1): 17-31.Conant R, Schauss AG. Therapeutic Applications of Citicoline for Stroke and Cognitive Dysfunction in the Elderly: A Review of the Literature. Alternative Medicine Review, 2004, 9(1): 17-31.Overgaard K. The Effects of Citicoline on Acute Ischemic Stroke: A Review. Journal of Stroke and Cerebrovascular Diseases, 2014, 23(7): 1764-1769.Overgaard K. The Effects of Citicoline on Acute Ischemic Stroke: A Review. Journal of Stroke and Cerebrovascular Diseases, 2014, 23(7): 1764-1769.Amenta F, Tullio MDi, Tomassoni D.The cholinergic approach for the treatment of vascular dementia: evidence from pre-clinical and clinical studies. Clin. Exp. Hypertens., 2002, 24: 697-713.Amenta F, Tullio MDi, Tomassoni D.The cholinergic approach for the treatment of vascular dementia: evidence from pre-clinical and clinical studies. Clin. Exp. Hypertens., 2002, 24: 697-713.Alvarez-Sabin J, Roman G. Citicoline in vascular cognitive impairment and vascular dementia after stroke. Stroke, 2011, 42(Suppl. 1): 40-3.Alvarez-Sabin J, Roman G. Citicoline in vascular cognitive impairment and vascular dementia after stroke. Stroke, 2011, 42(Suppl. 1): 40-3.Alvarez X et al. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer’s disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Methods Find Exp Clin Pharmacol, 1999, 9: 633-44.Alvarez X et al. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer’s disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Methods Find Exp Clin Pharmacol, 1999, 9: 633-44.Clark W et al. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology, 1997, 49: 671-8.Clark W et al. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology, 1997, 49: 671-8.Dаvalos A. et al. Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. Stroke, 2002, 33: 2850-7.Dаvalos A. et al. Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. Stroke, 2002, 33: 2850-7.Парфенов В.А., Фатеева Т.Г., Косивцова О.В. Клинический опыт применения Цераксона при ишемическом инсульте. Неврология. Нейропсихиатрия. Психосоматика, 2010, 3: 67-70.Парфенов В.А., Фатеева Т.Г., Косивцова О.В. Клинический опыт применения Цераксона при ишемическом инсульте. Неврология. Нейропсихиатрия. Психосоматика, 2010, 3: 67-70.Dávalos A et al. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet, 2012, 380(9839): 349-57.Dávalos A et al. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet, 2012, 380(9839): 349-57.Cotroneo A et al. Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study. Clin. Interv. Aging., 2013, 8: 131-137.Cotroneo A et al. Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study. Clin. Interv. Aging., 2013, 8: 131-137.

The authors declare that there are no conflicts of interest present.